Showing 1 - 10 of 39
With more than 125,000 reported cases of COVID-19 in 118 countries, the global impact of the COVID-19 pandemic is evolving as the virus spreads. We consider the impact of the COVID-19 pandemic on the life sciences industry.
The current coronavirus outbreak (recently named COVID-19 by the World Health Organisation (WHO)) is dominating global headlines. Since it was first reported from Wuhan, China on 31 December 2019 it has spread to 25 countries, infected over 42,000 people and claimed over 1,000 lives.
Ransomware is one of the top threats for manufacturers in 2020. There have been an increasing number of targeted and paralysing attacks against European-based global producers, as evidenced by Picanol’s announcement last week.
As innovation and new technologies are rapidly transforming the way we live, it is imperative that businesses in all industries remain alive to the risks arising from these advancements.
With the pace of change in the global insurance market showing no signs of slowing in 2020, we have underlined the London Market’s need to reassert its ability to adapt and manage the constant evolution of global risk. Releasing our annual London Market forecast for the year ahead, we have made predictions across 11 areas impacting the London Market, namely: aviation, casualty coverage, construction, cyber, energy, financial lines, marine, product liability and life sciences, professions, political risks and property damage.
The pace of change in the global insurance market has not slowed down in the last 12 months, nor are there any indications of it doing so over the course of the coming year.
Boris Johnson’s first Queen’s Speech delivered on Monday 14 October 2019 - dominated by Brexit-related legislation - included the Medicines and Medical Devices Bill (the Bill).
Our product liability and life sciences team recently hosted their fifth life sciences conference which focused on emerging risks in innovative healthcare technology.
Lab-grown meat is not just the latest product for environmentally conscious consumers, it also heralds a new type of agriculture and food product design, which could offer attractive risk profiles for insurers that get to know the science.
Case review 14/11/2019
In Bailey & Ors v GlaxoSmithKline “The Seroxat Group Litigation” [08.11.19] the Court of Appeal decided that it was impermissible for the claimants to expand the scope of their pleaded case at trial, which was previously determined at both the case management stage and during the pre-trial review.